BIOCON LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 309.2 INR | -0.51% |
|
-3.19% | +23.87% |
| 24/05 | INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh | RE |
| 24/05 | Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea | MT |
| Sales 2024 | 148B 1.77B | Sales 2025 * | 161B 1.93B | Capitalization | 369B 4.43B |
|---|---|---|---|---|---|
| Net income 2024 | 10.22B 123M | Net income 2025 * | 9.43B 113M | EV / Sales 2024 | 2.14 x |
| Net Debt 2024 * | 139B 1.67B | Net Debt 2025 * | 131B 1.57B | EV / Sales 2025 * | 3.11 x |
| P/E ratio 2024 |
30.9
x | P/E ratio 2025 * |
40.2
x | Employees | 16,545 |
| Yield 2024 * |
0.47% | Yield 2025 * |
0.29% | Free-Float | 37.18% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biocon Limited
More recommendations
More press releases
More news
| 1 day | -0.51% | ||
| 1 week | -3.19% | ||
| 1 month | +3.58% | ||
| 3 months | +11.84% | ||
| 6 months | +29.77% | ||
| Current year | +23.87% |
1 week
305.40
325.80
1 month
292.20331.00
Current year
244.55331.00
1 year
217.50331.00
3 years
191.55420.25
5 years
191.55487.75
10 years
65.88487.75
| Managers | Title | Age | Since |
|---|---|---|---|
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 01/13/01 |
Peter Bains
CEO | Chief Executive Officer | 65 | 12/22/12 |
| Chairman | 71 | 29/78/29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 29/78/29 | |
| Director/Board Member | 69 | 01/00/01 | |
| Director/Board Member | 60 | 27/18/27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.17% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 309.2 | -0.51% | 5,589,376 |
| 30/24/30 | 310.8 | -3.94% | 9,357,893 |
| 29/24/29 | 323.6 | +1.84% | 8,347,446 |
| 28/24/28 | 317.8 | +0.89% | 8,345,701 |
| 27/24/27 | 315 | -1.41% | 11,540,430 |
Delayed Quote NSE India S.E., May 31, 2024 at 05:13 pm IST
More quotes
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Calendar
05/07/2024
- Ex-dividend day for final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
309.2
INR
Average target price
292.6
INR
Spread / Average Target
-5.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.87% | 4.42B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- BIOCON Stock
